Respiratory syncytial virus fusion glycoprotein expressed in insect cells form protein nanoparticles that induce protective immunity in cotton rats
about
Self-assembling protein nanoparticles in the design of vaccinesStructure-Based Design of Head-Only Fusion Glycoprotein Immunogens for Respiratory Syncytial VirusImmunogenicity and safety of a respiratory syncytial virus fusion protein (RSV F) nanoparticle vaccine in older adults.Mucosal vaccines against respiratory syncytial virusModification of the respiratory syncytial virus f protein in virus-like particles impacts generation of B cell memory.Current concepts and progress in RSV vaccine development.A highly stable prefusion RSV F vaccine derived from structural analysis of the fusion mechanismRecombinant influenza virus expressing a fusion protein neutralizing epitope of respiratory syncytial virus (RSV) confers protection without vaccine-enhanced RSV diseasePalivizumab epitope-displaying virus-like particles protect rodents from RSV challenge.Mucosal delivery of a vectored RSV vaccine is safe and elicits protective immunity in rodents and nonhuman primates.Murine immune responses to virus-like particle-associated pre- and postfusion forms of the respiratory syncytial virus F proteinRespiratory syncytial virus, an ongoing medical dilemma: an expert commentary on respiratory syncytial virus prophylactic and therapeutic pharmaceuticals currently in clinical trialsDevelopment of Acquired Immunity following Repeated Respiratory Syncytial Virus Infections in Cotton Rats.Engineering, Structure and Immunogenicity of the Human Metapneumovirus F Protein in the Postfusion Conformation.Cotton rat immune responses to virus-like particles containing the pre-fusion form of respiratory syncytial virus fusion protein.Sendai virus as a backbone for vaccines against RSV and other human paramyxovirusesStructural basis for nonneutralizing antibody competition at antigenic site II of the respiratory syncytial virus fusion protein.Recent advances in diagnosis, prevention, and treatment of human respiratory syncytial virus.Structural, antigenic and immunogenic features of respiratory syncytial virus glycoproteins relevant for vaccine development.A recombinant anchorless respiratory syncytial virus (RSV) fusion (F) protein/monophosphoryl lipid A (MPL) vaccine protects against RSV-induced replication and lung pathology.Development of an adenovirus-based respiratory syncytial virus vaccine: preclinical evaluation of efficacy, immunogenicity, and enhanced disease in a cotton rat model.Respiratory syncytial virus: current progress in vaccine development.Update on baculovirus as an expression and/or delivery vehicle for vaccine antigens.Gene sequence variability of the three surface proteins of human respiratory syncytial virus (HRSV) in TexasNovel therapies and vaccines against the human respiratory syncytial virus.Respiratory Syncytial Virus: The Influence of Serotype and Genotype Variability on Clinical Course of Infection.Understanding respiratory syncytial virus (RSV) vaccine development and aspects of disease pathogenesis.Ebola virus disease candidate vaccines under evaluation in clinical trials.Development of an intradermal DNA vaccine delivery strategy to achieve single-dose immunity against respiratory syncytial virus.A Single-Dose Recombinant Parainfluenza Virus 5-Vectored Vaccine Expressing Respiratory Syncytial Virus (RSV) F or G Protein Protected Cotton Rats and African Green Monkeys from RSV Challenge.A safe and efficient BCG vectored vaccine to prevent the disease caused by the human Respiratory Syncytial Virus.Dynamics of 8G12 competitive antibody in "prime-boost" vaccination of Hepatitis E vaccine.A Respiratory Syncytial Virus Vaccine Vectored by a Stable Chimeric and Replication-Deficient Sendai Virus Protects Mice without Inducing Enhanced Disease.MERS-CoV spike nanoparticles protect mice from MERS-CoV infection.Purified coronavirus spike protein nanoparticles induce coronavirus neutralizing antibodies in mice.Experimental animal model for analyzing immunobiological responses following vaccination with formalin-inactivated respiratory syncytial virus.Influence of antigen conformation and mode of presentation on the antibody and protective responses against human respiratory syncytial virus: relevance for vaccine development.A gene deletion that up-regulates viral gene expression yields an attenuated RSV vaccine with improved antibody responses in children.The preventive effect of vaccine prophylaxis on severe respiratory syncytial virus infection: A meta-analysis.A Randomized, Blinded, Controlled, Dose-Ranging Study of a Respiratory Syncytial Virus Recombinant Fusion (F) Nanoparticle Vaccine in Healthy Women of Childbearing Age.
P2860
Q26767097-B8B4AF8C-EC50-48E8-B920-805B6F14B5C4Q27333522-A217E2AF-96F8-432B-AF9F-9A85FFF6C2EFQ33555911-AC91E3FD-F692-44B4-ACFE-71101121B670Q33837530-3EEA661A-0D7D-453F-BD81-A92F77FCA4EAQ34059404-9E5DDC3A-8B1B-40FF-8976-7FB0653B2AC8Q34396689-89E47FC7-E1E4-4640-A6F9-3C4DBA8D3407Q34492100-D3AA2611-4716-4CB0-8B92-30E84F21BB03Q35070176-7C43D9AF-8E73-4556-9B20-F17DBCA31EF0Q35535626-029B53C0-14D8-49F0-B703-E86803341933Q35635434-F777ED68-5E18-4340-BE18-490F7B6567C5Q35745343-86B8EBB9-8F64-4B6D-BBE1-DB29CAC1F09BQ35761061-1F66EE46-50ED-4010-86E8-3DF5F87F74D7Q36029171-3C5F08AB-97B2-43CB-9970-58C5D98606C9Q36128048-FA0E99C7-44E5-417D-8AA2-B3AC444DCED7Q36256989-A5541446-CC91-4B2D-8009-F0F327270705Q37118707-3F751E3B-A75C-415A-BFF0-E65AC0EF98D8Q37398188-AAC3E5E3-326E-4B90-97AE-5198A8F339E6Q37412509-2F82B4A6-DD93-449A-BE9E-4C9AAEA1432BQ37536191-99E523D8-0E89-45A0-B5A6-F670CD4D9745Q37627348-99916B13-263F-4106-9751-731CDAE45AA7Q37713960-AE33EE0E-D332-412A-B61C-A22D15BC1D67Q38079432-9D8DE7D8-8115-47A7-A88B-4B2D8B585422Q38243160-336B4215-72FC-4532-92A0-2F4F122B1634Q38267482-2B3497D2-E19C-4374-A894-854F08C90A3AQ38604787-A8BD51A7-9ABA-48F8-A1A2-EAFBEAD90FE7Q38637248-63635C62-1B4E-4942-BA28-E1A3FFAE3994Q38660842-609C8E8A-DB62-4E82-827B-252ABE06DFF7Q38830109-9EF7082D-1333-43E5-8848-0690490B9624Q38835118-89B59601-7462-4B15-B778-4BA9457B09D3Q38905050-3E850C3F-2B47-4C7E-BDCB-46B1B0956532Q39362187-A3155215-37B8-4513-BD05-C60DB8A075A3Q40302625-F47EB670-D89D-4C84-9933-19FF4A92F8B7Q40312271-F6B072D3-E898-499B-AD40-9345384857D7Q40317741-529607BE-BE17-47ED-8823-AE92B289305DQ40744757-524C4939-48D7-4A0A-89EE-7A4DAB42F729Q40796422-5E85F48A-A894-4FD1-8D12-1F588C28A720Q40812866-A0898AA9-8C7D-4FD1-99CC-9C5670869D14Q40922844-FB2591A1-A0C3-423F-B2C2-9D825EDCF55EQ40933366-323499B2-A64E-4AB0-8579-E446DE74BC8FQ41060727-3CF0FA06-3632-43F1-81DA-B4D0F7C846D0
P2860
Respiratory syncytial virus fusion glycoprotein expressed in insect cells form protein nanoparticles that induce protective immunity in cotton rats
description
2012 nî lūn-bûn
@nan
2012 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2012 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
name
Respiratory syncytial virus fu ...... ective immunity in cotton rats
@ast
Respiratory syncytial virus fu ...... ective immunity in cotton rats
@en
Respiratory syncytial virus fu ...... ective immunity in cotton rats
@nl
type
label
Respiratory syncytial virus fu ...... ective immunity in cotton rats
@ast
Respiratory syncytial virus fu ...... ective immunity in cotton rats
@en
Respiratory syncytial virus fu ...... ective immunity in cotton rats
@nl
prefLabel
Respiratory syncytial virus fu ...... ective immunity in cotton rats
@ast
Respiratory syncytial virus fu ...... ective immunity in cotton rats
@en
Respiratory syncytial virus fu ...... ective immunity in cotton rats
@nl
P2093
P2860
P1433
P1476
Respiratory syncytial virus fu ...... ective immunity in cotton rats
@en
P2093
David Flyer
Gale Smith
Gregory Glenn
Jingning Li
Margret Nathan
Michael Massare
Rama Raghunandan
Sarathi Boddapati
P2860
P304
P356
10.1371/JOURNAL.PONE.0050852
P407
P577
2012-11-30T00:00:00Z